Moderna Faces Analyst Downgrades Amid Revised R&D Restructured Strategy and Delayed Profitability Target
Portfolio Pulse from Vandana Singh
Moderna Inc (NASDAQ:MRNA) announced a reduction in R&D spending and a focus on ten prioritized products, aiming for ten product approvals in three years. Analysts have downgraded the stock, citing delayed profitability and challenges in the respiratory vaccine market. The stock closed lower by 2.01%.
September 13, 2024 | 10:34 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Moderna's INT Oncology program, developed in partnership with Merck, offers potential upside but progress is slow. Revenue from this program is unlikely before 2027.
The INT Oncology program with Merck is highlighted as having potential upside, but slow progress means it won't impact Merck's financials in the short term. Thus, the immediate impact on Merck's stock is neutral.
CONFIDENCE 80
IMPORTANCE 50
RELEVANCE 30
NEGATIVE IMPACT
Moderna announced a $1.1 billion reduction in R&D spending by 2027, focusing on ten prioritized products. Analysts downgraded the stock due to delayed profitability and challenges in the respiratory vaccine market. The stock closed 2.01% lower.
Moderna's announcement of reduced R&D spending and a focus on prioritized products led to analyst downgrades. The delay in profitability and challenges in the respiratory vaccine market contributed to a negative outlook, resulting in a 2.01% drop in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100